



Département de psychiatrie
Centre de neurosciences psychiatriques
Site de Cery
CH-1008 Prilly - Lausanne

Centre de Neurosciences Psychiatriques

CNP SEMINAR

ANNOUNCEMENT

Wednesday, July 2, 2014, 11:00

**“Glutamate-based treatment for schizophrenia:
where do we go from here?”**

Dr Daniel C. Javitt

Director, Div. of Experimental Therapeutics Director
Columbia Conte Center for Schizophrenia
Columbia University College of Physicians and Surgeons, NY

Director, Division of Schizophrenia Research,
Nathan Kline Institute for Psychiatric Research; NY
email: dcj2113@columbia.edu/javitt@nki.rfmh.org

Invited by Kim Do Cuénod
(Kim.Do@chuv.ch)

**Auditoire, Hôpital Psychiatrique de Cery
Site de Cery, CH-1008 Prilly-Lausanne**

Selected Publications:

1. Javitt, D.C., et al. Translating glutamate: from pathophysiology to treatment. *Science translational medicine* 3, 102mr102 (2011).
2. *Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology*. 2012;37(1):4-15. Epub 2011/10/01.
3. Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. *Mol Psychiatry*. 2014;19(1):20-9.